Katy Moncivais

Written by Katy Moncivais, PhD on March 18, 2026 Mesothelioma life expectancies have improved in recent years. This change is largely thanks to the approval of a new immunotherapy regimen. Opdivo (nivolumab) and Yervoy (ipilimumab) have already boosted survival and quality of life. But what if something simple could make this combo even better? A growing body of research indicates immunotherapy infusion timing strongly impacts prognosis.

Next-Gen Treatment Monitoring Researchers shared a novel solution to an old problem this year. When any cancer patient undergoes treatment, doctors try to monitor its success. This helps them decide whether to stick with a specific drug or possibly switch to a different one. For mesothelioma, it can be tough to tell if treatment is working. Traditional imaging techniques might make tumors look bigger or smaller than they are.

Next-Gen Treatment Monitoring Researchers shared a novel solution to an old problem this year. When any cancer patient undergoes treatment, doctors try to monitor its success. This helps them decide whether to stick with a specific drug or possibly switch to a different one. For mesothelioma, it can be tough to tell if treatment is working. Traditional imaging techniques might make tumors look bigger or smaller than they are.